Destiny Pharma PLC (AIM:DEST) said preparations for the phase 3 trial of its C-difficile treatment (NTCD-M3) are going well.
In a trading update detailing its plans for 2022, the AIM-listed biotech added it had made good progress in licensing discussions for NTCD-M3 while supportive microbiological research is also underway with results to be announced in the first quarter of this year.
Elsewhere, discussions with regulators over a final-stage trial of its nasal gel (XF-73) to prevent post-surgical infections are expected to conclude within this half-year.
A market research project is underway to update the understanding of the requirements of infectious disease physicians and payers in key European markets with regard to nasal decolonisation.
Ultimately, Destiny Pharma estimates that global peak sales for XF-73 nasal gel could exceed US$1bn while the market for NTCD-M3 might be worth US$500mln in the US alone.
Preclinical work on SPOR-COV, designed to prevent coronavirus infections, is progressing as planned, noted the statement.
Neil Clark, chief executive added: "Destiny Pharma starts 2022 with a diversified and valuable drug pipeline targeted at infection prevention.
“We are now focused on the finalisation of the Phase 3 trial plans for our two, differentiated, late-stage clinical assets and closing partnering deals.”